Importantly, since we have identified the NLRP3 inflammasome as the source of IL-18 in CpG-induced MAS, targeting the NLRP3 inflammasome in patients with MAS – where IL-18 signalling is crucial – could be an effective treatment to alleviate the disease. This evidence concerns the gene IL18 and macrophage activation syndrome.